ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
Examination of the structural basis for antiviral activity, oral pharmacokinetics, and hepatic metabolism among a series of symmetry-based inhibitors of the human immunodeficiency virus (HIV) protease led to the discovery of ABT-538, a promising experimental drug for the therapeutic intervention in...
Guardat en:
| Publicat a: | Proc Natl Acad Sci U S A |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
National Academy of Sciences
1995
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC42242/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/7708670/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.92.7.2484 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
